These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Tissue plasminogen activator, a new specific thrombolytic of fibrin. Molecular mechanisms and clinical application]. Verstraete M; Collen D Bull Acad Natl Med; 1985 Oct; 169(7):1109-16. PubMed ID: 3938670 [No Abstract] [Full Text] [Related]
8. [Anticoagulation in thrombolytic therapy: importance and future perspectives]. Harenberg J; Heene DL Z Gesamte Inn Med; 1993; 48(6-7):283-8. PubMed ID: 8333224 [TBL] [Abstract][Full Text] [Related]
9. [Further data on therapeutic fibrinolysis]. Schmutzler R Helv Med Acta; 1963 Nov; 30(4):608-14. PubMed ID: 5878830 [No Abstract] [Full Text] [Related]
10. Thrombolytic therapy: current status (2). Marder VJ; Sherry S N Engl J Med; 1988 Jun; 318(24):1585-95. PubMed ID: 3287158 [No Abstract] [Full Text] [Related]
11. [Indications for thrombolytics]. Charbonnier B Rev Prat; 1999 Oct; 49(15):1659-63. PubMed ID: 10581997 [TBL] [Abstract][Full Text] [Related]
12. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
13. [Which indications for thrombolytic therapy proved competent?]. van de Loo J ZFA (Stuttgart); 1977 May; 53(15):855-60. PubMed ID: 883379 [No Abstract] [Full Text] [Related]